Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene.

Molecular Cancer
Haiqing MaJianchuan Xia

Abstract

High frequency of loss of heterozygosity (LOH) was found at D7S486 in primary gastric cancer (GC). And we found a high frequency of LOH region on 7q31 in primary GC from China, and identified D7S486 to be the most frequent LOH locus. This study was aimed to determine what genes were affected by the LOH and served as tumor suppressor genes (TSGs) in this region. Here, a high-throughput single nucleotide polymorphisms (SNPs) microarray fabricated in-house was used to analyze the LOH status around D7S486 on 7q31 in 75 patients with primary GC. Western blot, immunohistochemistry, and RT-PCR were used to assess the protein and mRNA expression of TESTIN (TES) in 50 and 140 primary GC samples, respectively. MTS assay was used to investigate the effect of TES overexpression on the proliferation of GC cell lines. Mutation and methylation analysis were performed to explore possible mechanisms of TES inactivation in GC. LOH analysis discovered five candidate genes (ST7, FOXP2, MDFIC, TES and CAV1) whose frequencies of LOH were higher than 30%. However, only TES showed the potential to be a TSG associated with GC. Among 140 pairs of GC samples, decreased TES mRNA level was found in 96 (68.6%) tumor tissues when compared with matched non-tu...Continue Reading

References

Jan 1, 1996·Human Mutation·J M ShumakerC T Caskey
Mar 24, 2000·Trends in Genetics : TIG·S B Baylin, J G Herman
Apr 7, 2004·Current Oncology Reports·Alexandria T Phan, Jaffer A Ajani
Jul 15, 2004·International Journal of Cancer. Journal International Du Cancer·Laurent ChêneAlain Latil
Jul 22, 2005·Proceedings of the National Academy of Sciences of the United States of America·Alessandra DruscoCarlo M Croce
Nov 22, 2005·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·Q HuangS P Schantz
Apr 25, 2006·Cancer Genetics and Cytogenetics·Jian-Chuan XiaYi-Xing Zeng
May 12, 2006·World Journal of Gastroenterology : WJG·De-Sheng WengJian-Chuan Xia
Oct 22, 2008·Virchows Archiv : an International Journal of Pathology·V BarresiG Tuccari
Feb 4, 2011·The American Journal of Clinical Nutrition·Romain Barres, Juleen R Zierath

❮ Previous
Next ❯

Citations

Feb 15, 2011·Journal of Biomedicine & Biotechnology·Alessandra DruscoNicola Zanesi
Dec 19, 2012·Spermatogenesis·Shailendra Kapoor
Dec 3, 2016·Oncology Letters·Giedrius SteponaitisPaulina Vaitkiene
May 5, 2018·Genes & Cancer·Maria Jesus Herrero, Yorick Gitton
Apr 30, 2013·Journal of Neuro-oncology·Daina SkiriutėArimantas Tamašauskas
May 30, 2013·Oncology Reports·Manuela SartiCarlo V Catapano

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
transfection
flow cytometry
surgical resection
PCR
electrophoresis

Software Mentioned

AccTyping
SPSS

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Caveolins & Signal Transduction

Caveolins are small proteins with a hairpin loop conformation that are located in the plasma membrane of various cell types where they bind cholesterol and interact with receptors essential for several signal transduction pathways. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Related Papers

Trends in Biochemical Sciences
Kun-Liang Guan, Yue Xiong
Proceedings of the National Academy of Sciences of the United States of America
Alessandra DruscoCarlo M Croce
© 2021 Meta ULC. All rights reserved